text
stringlengths 6
1.29k
|
|---|
disease on hemodialysis. Thyroid 15:1321–1331. 911. Driedger AA, Quirk S, McDonald TJ, Ledger S, Gray D, Wall W, Yoo J 2006 A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure. Clin Nucl Med 31:454–457. 912. Jarzab B, Handkiewicz-Junak D, Wloch J 2005 Juvenile differentiated thyroid carcinoma and the role of radio- iodine in its treatment: a qualitative review. Endocr Relat Cancer 12:773–803. 913. Verburg FA, Biko J, Diessl S, Demidchik Y, Drozd V, Rivkees SA, Reiners C, Hanscheid H 2011 I-131 activ- ities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer. J Clin Endocrinol Metab 96:E1268–E1271. 914. Ma C, Xie J, Liu W, Wang G, Zuo S, Wang X, Wu F 2010 Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differ- entiated thyroid cancer. Cochrane Database Syst Rev (11): CD008302. 915. Klubo-Gwiezdzinska J, |
Van Nostrand D, Atkins F, Burman K, Jonklaas J, Mete M, Wartofsky L 2011 Ef- ficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. J Clin Endocrinol Metab 96:3217–3225. 916. Lee JJ, Chung JK, Kim SE, Kang WJ, Park do J, Lee DS, Cho BY, Lee MC 2008 Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med 22: 727–734. 917. Samuel AM, Rajashekharrao B, Shah DH 1998 Pulmon- ary metastases in children and adolescents with well- differentiated thyroid cancer. J Nucl Med 39:1531–1536. 918. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ, Larson SM 2004 Patient-specific do- simetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45:1366–1372. 919. Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, |
Bockisch A 2008 Optimized 124I PET dosim- etry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med 49:1017–1023. 920. Pettinato C, Monari F, Nanni C, Allegri V, Marcatili S, Civollani S, Cima S, Spezi E, Mazzarotto R, Fanti S 2012 Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I. Q J Nucl Med Mol Imaging 56:509–514.126 HAUGEN ET AL. |
921. Reiners C, Biko J, Haenscheid H, Hebestreit H, Kirinjuk S, Baranowski O, Marlowe RJ, Demidchik E, Drozd V, Demidchik Y 2013 Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and ado- lescents with very high-risk radiation-induced differen- tiated thyroid carcinoma. J Clin Endocrinol Metab 98: 3039–3048. 922. Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM 2007 Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of pa- tients. Nat Clin Pract Endocrinol Metab 3:260–269. 923. Kulkarni K, Van Nostrand D, Atkins F, Aiken M, Bur- man K, Wartofsky L 2006 The relative frequency inwhich empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid 16:1019– 1023. 924. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, Chan CY 2006 Empiric radioactive io- dine dosing regimens frequently exceed maximum tol- erated |
activity levels in elderly patients with thyroid cancer. J Nucl Med 47:1587–1591. 925. Rudavsky AZ, Freeman LM 1997 Treatment of scan- negative, thyroglobulin-positive metastatic thyroid can- cer using radioiodine 131I and recombinant human thy- roid stimulating hormone. J Clin Endocrinol Metab 82: 11–14. 926. Ringel MD, Ladenson PW 1996 Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J Clin Endocrinol Metab 81:1724–1725. 927. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C 2000 Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin En- docrinol Metab 85:3640–3645. 928. Mariani G, Ferdeghini M, Augeri C, Villa G, Taddei GZ, Scopinaro G, Boni G, Bodei L, Rabitti C, Molinari E, Bianchi R 2000 Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of pa- tients with differentiated |
thyroid cancer. Cancer Biother Radiopharm 15:211–217. 929. Perros P 1999 Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. J En-docrinol Invest 22:30–34. 930. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, Pacini F 2001 Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L- thyroxine, using recombinant human TSH. Eur J En- docrinol 144:5–11. 931. Pellegriti G, Scollo C, Giuffrida D, Vigneri R, Squatrito S, Pezzino V 2001 Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid 11:1025–1030. 932. Adler ML, Macapinlac HA, Robbins RJ 1998 Radio- iodine treatment of thyroid cancer with the aid of re- combinant human thyrotropin. Endocr Pract 4:282–286. 933. Chiu AC, Delpassand ES, Sherman SI 1997 Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82:3637–3642. 934. Lau WF, Zacharin MR, Waters |
K, Wheeler G, Johnston V, Hicks RJ 2006 Management of paediatric thyroidcarcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radio- iodine therapy. Intern Med J 36:564–570. 935. Potzi C, Moameni A, Karanikas G, Preitfellner J, Be- cherer A, Pirich C, Dudczak R 2006 Comparison of io- dine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant hu- man thyrotropin in thyroid cancer patients. Clin En- docrinol (Oxf) 65:519–523. 936. Vargas GE, Uy H, Bazan C, Guise TA, Bruder JM 1999 Hemiplegia after thyrotropin alfa in a hypothyroid pa- tient with thyroid carcinoma metastatic to the brain. JClin Endocrinol Metab 84:3867–3871. 937. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM 2000 Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. Endocr Pract 6:460–464. 938. Braga M, Ringel MD, Cooper DS 2001 Sudden en- largement |
of local recurrent thyroid tumor after recom- binant human TSH administration. J Clin Endocrinol Metab 86:5148–5151. 939. Pons F, Carrio I, Estorch M, Ginjaume M, Pons J, Milian R 1987 Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. Clin Nucl Med 12:644–647. 940. Koong SS, Reynolds JC, Movius EG, Keenan AM, Ain KB, Lakshmanan MC, Robbins J 1999 Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 84:912–916. 941. Liu YY, van der Pluijm G, Karperien M, Stokkel MP, Pereira AM, Morreau J, Kievit J, Romijn JA, Smit JW 2006 Lithium as adjuvant to radioiodine therapy in dif- ferentiated thyroid carcinoma: clinical and in vitro studies. Clin Endocrinol (Oxf) 64:617–624. 942. Ronga G, Filesi M, Montesano T, Di Nicola AD, Pace C, Travascio L, Ventroni G, Antonaci A, Vestri AR 2004 Lung metastases from differentiated |
thyroid carcinoma. A 40 years’ experience. Q J Nucl Med Mol Imaging 48: 12–19. 943. Lin JD, Chao TC, Chou SC, Hsueh C 2004 Papillary thyroid carcinomas with lung metastases. Thyroid 14: 1091–1096. 944. Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, Shah JP, Shaha AR 2003 Prognostic indicators of outcomes in patients with distantmetastases from differentiated thyroid carcinoma. J Am Coll Surg 197:191–197. 945. Zettinig G, Fueger BJ, Passler C, Kaserer K, Pirich C, Dudczak R, Niederle B 2002 Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma—surgery or conventional therapy? Clin En- docrinol (Oxf) 56:377–382. 946. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, Robbins RJ 2000 Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 10: 261–268. 947. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso |
JD, Francese C, Fontaine F, Ricard M, Parmentier C 1996 Radioactive iodine treat- ment and external radiotherapy for lung and bone me- tastases from thyroid carcinoma. J Nucl Med 37:598– 605.ATA THYROID NODULE/DTC GUIDELINES 127 |
948. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID 1995 Distant metastases in papil- lary thyroid carcinoma: 100 cases observed at one in- stitution during 5 decades. J Clin Endocrinol Metab 80: 2041–2045. 949. Foote RL, Brown PD, Garces YI, McIver B, Kasperbauer JL 2003 Is there a role for radiation therapy in the management of Hu ¨rthle cell carcinoma? Int J Radiat Oncol Biol Phys 56:1067–1072. 950. Pak H, Gourgiotis L, Chang WI, Guthrie LC, Skarulis MC, Reynolds JC, Merino MJ, Schrump DS, Libutti SK, Alexander HR Jr, Sarlis NJ 2003 Role of metastasectomy in the management of thyroid carcinoma: the NIH ex-perience. J Surg Oncol 82:10–18. 951. Vitale G, Fonderico F, Martignetti A, Caraglia M, Cic- carelli A, Nuzzo V, Abbruzzese A, Lupoli G 2001 Pa- midronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. |
Br J Cancer 84:1586–1590. 952. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, Ito K, Ito K, Tanaka S 1999 Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 84: 4043–4049. 953. Brose MS, Smit J, Capdevila J, Elisei R, Nutting C, Pi- toia F, Robinson B, Schlumberger M, Shong YK, Ta- kami H 2012 Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther 12:1137–1147. 954. Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, Tuttle RM, Fagin JA 2013 Clinical out- comes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab 98:E829–E836. 955. Benua RS, Cicale NR, Sonenberg M, Rawson RW 1962 The relation of radioiodine dosimetry to results and com- plications in the treatment of metastatic thyroid cancer. Am J |
Roentgenol Radium Ther Nucl Med 87:171–182. 956. Hebestreit H, Biko J, Drozd V, Demidchik Y, Burkhardt A, Trusen A, Beer M, Reiners C 2011 Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl. Eur J Nucl Med Mol Imaging 38:1683–1690. 957. Ilgan S, Karacalioglu AO, Pabuscu Y, Atac GK, Arslan N, Ozturk E, Gunalp B, Ozguven MA 2004 Iodine-131treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 31:825–830. 958. Hod N, Hagag P, Baumer M, Sandbank J, Horne T 2005 Differentiated thyroid carcinoma in children and young adults: evaluation of response to treatment. Clin Nucl Med 30:387–390. 959. Van Nostrand D, Freitas J 2006 Side effects of 131I for ablation and treatment of well differentiated thyroid car- cinoma. In: Wartofsky L, Van Nostrand D (eds) Thyroid Cancer: A Comprehensive Guide to Clinical |
Management. 2nd edition. Humana Press, Totowa, NJ, pp 459–485. 960. Lang BH, Wong IO, Wong KP, Cowling BJ, Wan KY 2012 Risk of second primary malignancy in differenti- ated thyroid carcinoma treated with radioactive iodine therapy. Surgery 151:844–850. 961. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP 2009Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19:451–457. 962. Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA 2002 Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan- negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 87:1521–1526. 963. Koh JM, Kim ES, Ryu JS, Hong SJ, Kim WB, Shong YK 2003 Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparativestudy. Clin Endocrinol (Oxf) |
58:421–427. 964. Ma C, Kuang A, Xie J 2009 Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. Cochrane Database Syst Rev1–38. 965. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ 2001 Resistance of [18f]- fluorodeoxyglucose-avid metastatic thyroid cancer le- sions to treatment with high-dose radioactive iodine. Thyroid 11:1169–1175. 966. Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D’Amico D, Della Morte AM, Pace L, Salvatore M 2008 Fluorodeoxyglucose PET/CT in patients with differenti- ated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. Q J Nucl Med Mol Imaging 52:2–8. 967. Kloos RT 2008 Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab 93:1519–1525. 968. van Tol KM, Jager PL, de Vries EG, Piers DA, Boezen HM, Sluiter |
WJ, Dullaart RP, Links TP 2003 Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimu- lated thyroglobulin. Eur J Endocrinol 148:589–596. 969. Kabasakal L, Selcuk NA, Shafipour H, Ozmen O, Onsel C, Uslu I 2004 Treatment of iodine-negative thyroglobulin- positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. Eur J Nucl Med Mol Imaging 31:1500–1504. 970. Yim JH, Kim EY, Bae KW, Kim WG, Kim TY, Ryu JS, Gong G, Hong SJ, Yoon JH, Shong YK 2013 Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer. Thyroid 23:58–63. 971. Black EG, Sheppard MC, Hoffenberg R 1987 Serial se- rum thyroglobulin measurements in the management of differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 27:115–120. 972. Huang SH, Wang PW, Huang YE, Chou FF, Liu RT, Tung SC, Chen JF, Kuo MC, Hsieh JR, Hsieh HH 2006 Sequential follow-up of serum thyroglobulin |
and whole body scan in thyroid cancer patients without initial me- tastasis. Thyroid 16:1273–1278. 973. Schlumberger M, Mancusi F, Baudin E, Pacini F 1997 131I therapy for elevated thyroglobulin levels. Thyroid 7:273–276. 974. Ma C, Xie J, Kuang A 2005 Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results? J Nucl Med 46:1164–1170. 975. Chao M 2010 Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic128 HAUGEN ET AL. |
radioiodine whole body scan. Clin Oncol (R Coll Radiol) 22:438–447. 976. Sinha P, Conrad GR, West HC 2011 Response of thyro- globulin to radioiodine therapy in thyroglobulin-elevated negative iodine scintigraphy (TENIS) syndrome. Antic- ancer Res 31:2109–2112. 977. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ 1994 Serum thyroglobulin in the follow- up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 79:98–105. 978. Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH, Yoon JH, Hong SJ, Kim ES, Kim TY, Kim WB, Shong YK 2010 Empiric high-dose 131-iodine therapy lacks efficacy fortreated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomog- raphy scan. J Clin Endocrinol Metab 95:1169–1173. 979. Biko J, Reiners C, Kreissl MC, Verburg FA, Demidchik Y, Drozd V 2011 Favourable course of disease after in- complete remission on (131)I therapy in children |
with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up. Eur J Nucl Med Mol Imaging 38:651– 655. 980. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C 1988 Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 29:1790–1794. 981. Walter MA, Turtschi CP, Schindler C, Minnig P, Muller- Brand J, Muller B 2007 The dental safety profile of high- dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med 48:1620–1625. 982. Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA 2002 Nasolacrimal drainage system obstruc- tion from radioactive iodine therapy for thyroid carci- noma. J Clin Endocrinol Metab 87:5817–5820. 983. Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scelo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, McBride ML, Kee-Seng C, Pompe- Kirn V, Kliewer EV, |
Tonita JM, Jonasson JG, Martos C, Boffetta P, Brennan P 2006 Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 91:1819–1825. 984. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, Straus S, Brierley JD, Tsang RW, Gafni A, Rotstein L, Sawka AM 2007 Secondprimary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 17:1277– 1288. 985. Almeida JP, Sanabria AE, Lima EN, Kowalski LP 2011 Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck 33:686–690. 986. Mandel SJ, Mandel L 2003 Radioactive iodine and the salivary glands. Thyroid 13:265–271. 987. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S 2005 Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 46:261–266. |
988. Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, Bockisch A, Stahl A 2010 The in- fluence of saliva flow stimulation on the absorbed radi- ation dose to the salivary glands during radioiodinetherapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging 37:2298–2306. 989. Van Nostrand D, Bandaru V, Chennupati S, Wexler J, Kulkarni K, Atkins F, Mete M, Gadwale G 2010 Radiopharmacokinetics of radioiodine in the parotid glands after the administration of lemon juice. Thyroid 20:1113–1119. 990. Bomeli SR, Schaitkin B, Carrau RL, Walvekar RR 2009 Interventional sialendoscopy for treatment of radioiodine- induced sialadenitis. Laryngoscope 119:864–867. 991. Prendes BL, Orloff LA, Eisele DW 2012 Therapeutic sialendoscopy for the management of radioiodine siala- denitis. Arch Otolaryngol Head Neck Surg 138:15–19. 992. Bhayani MK, Acharya V, Kongkiatkamon S, Farah S, Roberts DB, Sterba J, Chambers MS, Lai SY 2015 Sia- lendoscopy for patients |
with radioiodine-induced siala- denitis and xerostomia. Thyroid 25:834–838. 993. Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R 2001 The development of breast carcinoma in women with thyroid carcinoma. Cancer 92:225–231. 994. Perry WF, Hughes JF 1952 The urinary excretion and thyroid uptake of iodine in renal disease. J Clin Invest 31:457–463. 995. Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C 2002 Prognosis for fertility and ovarian function after treat- ment with radioiodine for thyroid cancer. Postgrad Med J 78:92–93. 996. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L 1995 Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 36:21–27. 997. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S, George SR, Goldstein DP 2008 A systematic review examining the effects of therapeutic radioactive iodine |
on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf) 69:479– 490. 998. Wu JX, Young S, Ro K, Li N, Leung AM, Chiu HK, Harari A, Yeh MW 2015 Reproductive outcomes and nononcologic complications after radioactive iodine ab- lation for well-differentiated thyroid cancer. Thyroid 25:133–138. 999. Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE, Pinchera A, Parmentier C1996 Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37:606–612. 1000. Garsi JP, Schlumberger M, Rubino C, Ricard M, Labbe M, Ceccarelli C, Schvartz C, Henri-Amar M, Bardet S, De Vathaire F 2008 Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ova- ries and outcome of pregnancies. J Nucl Med 49:845– 852. 1001. Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F 2001 131I therapy for differentiated thyroid |
cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab 86:3512– 3515. 1002. Bakheet SM, Powe J, Hammami MM 1998 Unilateral radioiodine breast uptake. Clin Nucl Med 23:170–171. 1003. Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, Edinboro CH, Rosenthal D, Thomas MJ,ATA THYROID NODULE/DTC GUIDELINES 129 |
Wexler JA, Asamoah E, Avram AM, Milas M, Greenlee C 2011 Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recom- mendations of the American Thyroid Association. Thy- roid21:335–346. 1004. Bernard N, Jantzem H, Becker M, Pecriaux C, Benard- Laribiere A, Montastruc JL, Descotes J, Vial T 2015 Severe adverse effects of bromocriptine in lactation inhibition: a pharmacovigilance survey. BJOG 122:1244–1251. 1005. Wichers M, Benz E, Palmedo H, Biersack HJ, Grunwald F, Klingmuller D 2000 Testicular function after radio- iodine therapy for thyroid carcinoma. Eur J Nucl Med 27:503–507. 1006. Hyer S, Vini L, O’Connell M, Pratt B, Harmer C 2002 Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf) 56: 755–758. 1007. Lushbaugh CC, Casarett GW 1976 The effects of go- nadal irradiation in clinical radiation therapy: a review. Cancer 37:1111–1125. 1008. Sarkar SD, Beierwaltes WH, Gill |
SP, Cowley BJ 1976 Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 17:460–464. 1009. Mazzaferri EL 2002 Gonadal damage from 131I therapy for thyroid cancer. Clin Endocrinol (Oxf) 57:313–314. 1010. Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, Pacini F 2014 Definition and man- agement of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2:356–358. 1011. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. 1012. Schlumberger M, Sherman SI 2012 Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 166:5–11. 1013. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt |
L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Pena C, Molnar I, Schlumberger MJ 2014 Sorafenib in radioactive iodine-refractory, locally advanced or meta- static differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384:319–328. 1014. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Dutcus CE, de las Heras B, Zhu J, Habra MA, Newbold K, Shah MH, Hoff AO, Gianou- kakis AG, Kiyota N, Hiram M, Kim SB, Krzyzanowska MK, Sherman SI 2014 A phase 3, multicenter, double- blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid can- cer (SELECT). J Clin Oncol 32:5S. (Abstract.). 1015. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben HM, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller |
RP 2011 Adjuvant whole- brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:134–141. 1016. Bonichon F, Palussie `re J, Godbert Y, Pulido M, Descat E, Devillers A, Meunier C, Leboulleux S, de Bae `re T,Galy-Lacour C, Lagoarde-Segot L, Cazeau AL 2013 Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study. Eur J Nucl Med Mol Imaging 40:1817–1827. 1017. Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Pa- piez L, Teh BS, lgarry RC, Cardenes HR, Timmerman RD 2010 Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 7:44–54. 1018. Lo SS, Fakiris AJ, Teh BS, Cardenes HR, Henderson MA, Forquer JA, Papiez L, lgarry RC, Wang JZ, Li K, Mayr NA, Timmerman RD 2009 Stereotactic body ra- diation therapy |
for oligometastases. Expert Rev Antic-ancer Ther 9:621–635. 1019. de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, Boige V, Lassau N, Marteau V, Lasser P, Roche A 2000 Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 175:1619–1625. 1020. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS 2001 Percutaneous radio-frequency ablation of hepatic me- tastases from colorectal cancer: long-term results in 117 patients. Radiology 221:159–166. 1021. de Baere T, Palussiere J, Auperin A, Hakime A, Abdel- Rehim M, Kind M, Dromain C, Ravaud A, Tebboune N, Boige V, Malka D, Lafont C, Ducreux M 2006 Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology 240:587–596. 1022. Lencioni R, Crocetti L, Cioni R, Suh R, Glenn |
D, Regge D, Helmberger T, Gillams AR, Frilling A, Ambrogi M, Bartolozzi C, Mussi A 2008 Response to radiofrequency ablation of pulmonary tumours: a prospective, intention- to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 9:621–628. 1023. Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP, Welch TJ, Wong GY, Sloan JA, Novotny PJ, Petersen IA, Beres RA, Regge D, Capanna R, Saker MB, Gronemeyer DH, Gevargez A, Ahrar K, Choti MA, de Baere TJ, Rubin J 2004 Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 22:300–306. 1024. Dupuy DE, Liu D, Hartfeil D, Hanna L, Blume JD, Ahrar K, Lopez R, Safran H, DiPetrillo T 2010 Percutaneous radiofrequency ablation of painful osseous metastases: amulticenter American College of Radiology Imaging Network trial. Cancer 116:989–997. 1025. Deandreis D, Leboulleux S, Dromain C, Auperin A, Coulot J, Lumbroso J, Deschamps F, Rao P, Schlum- |
berger M, de Baere T 2011 Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology 258:270–276. 1026. Wertenbroek MW, Links TP, Prins TR, Plukker JT, van der Jagt EJ, de Jong KP 2008 Radiofrequency ablation of hepatic metastases from thyroid carcinoma. Thyroid 18:1105–1110. 1027. Quan GM, Pointillart V, Palussiere J, Bonichon F 2012 Multidisciplinary treatment and survival of patients with vertebral metastases from thyroid carcinoma. Thyroid 22:125–130. 1028. Kurup AN, Callstrom MR 2010 Ablation of skeletal metastases: current status. J Vasc Interv Radiol 21:S242- S250.130 HAUGEN ET AL. |
1029. McWilliams RR, Giannini C, Hay ID, Atkinson JL, Stafford SL, Buckner JC 2003 Management of brain metastases from thyroid carcinoma: a study of 16 path- ologically confirmed cases over 25 years. Cancer 98: 356–362. 1030. Henriques de Figueiredo B, Godbert Y, Soubeyran I, Carrat X, Lagarde P, Cazeau AL, Italiano A, Sargos P, Kantor G, Loiseau H, Bonichon F 2014 Brain metastases from thyroid carcinoma: a retrospective study of 21 pa- tients. Thyroid 24:270–276. 1031. Chow CJ, Habermann EB, Abraham A, Zhu Y, Vickers SM, Rothenberger DA, Al-Refaie WB 2013 Does en- rollment in cancer trials improve survival? J Am CollSurg 216:774–780. 1032. Anderson RT, Linnehan JE, Tongbram V, Keating K, Wirth LJ 2013 Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid 23:392– 407. 1033. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gomez JM, |
Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ 2012 Vandetanib in locally advanced or metastatic dif- ferentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 13:897–905. 1034. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI 2015 Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621–630. 1035. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708–4713. 1036. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, |
Rubin J, Sideras K, Morris JC III, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C 2010 Efficacy of pazopanib in progressive, radioiodine- refractory, metastatic differentiated thyroid cancers: re- sults of a phase 2 consortium study. Lancet Oncol 11:962–972. 1037. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG 2010 Phase II study of daily sunitinib in FDG-PET-positive, iodine- refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional im- aging correlation. Clin Cancer Res 16:5260–5268. 1038. Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C 1990 Chemotherapy in metastatic non- anaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76:480–483. 1039. Schutz FA, Je Y, Richards CJ, Choueiri TK 2012 Meta- analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in |
patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 30:871–877. 1040. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E 2012 Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 167:643–650. 1041. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM 2011 Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based popula- tion. Eur J Endocrinol 165:315–322. 1042. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin |
Oncol 27:1675–1684. 1043. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O’Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714–4719. 1044. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL 2013 The non- investigational use of tyrosine kinase inhibitors in thy- roid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 98:31–42. 1045. Bible KC, Ain KB, Rosenthal MS 2014 Protein kinase inhibitor therapy in advanced thyroid cancer: ethical challenges and potential solutions. Int J Endocr Oncol 1:145–151. 1046. Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudet AL, Do Cao C, Chougnet CN, Leboulleux S, Baudin E, Schlumberger M, de la Fouchardiere C 2014 Tyrosine kinase inhibitor treat- ments in patients |
with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol 170:575–582. 1047. Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S 2009 Cardio- vascular toxicity following sunitinib therapy in meta- static renal cell carcinoma: a multicenter analysis. Ann Oncol 20:1535–1542. 1048. Harris PJ, Bible KC 2011 Emerging therapeutics for advanced thyroid malignancies: rationale and tar- geted approaches. Expert Opin Investig Drugs 20: 1357–1375. 1049. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB 2012 Dabrafenib in BRAF-mutated metastatic melano- ma: a multicentre, open-label, phase |
3 randomised con- trolled trial. Lancet 380:358–365. 1050. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O’Day SJ, Blackman SC, Curtis CM, Le- bowitz P, Ma B, Ouellet D, Kefford RF 2012 Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379:1893–1901. 1051. Kudchadkar R, Paraiso KH, Smalley KS 2012 Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J 18:124–131.ATA THYROID NODULE/DTC GUIDELINES 131 |
1052. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Dominguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA 2013 Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368:623–632. 1053. Spano JP, Vano Y, Vignot S, De La Motte RT, Hassani L, Mouawad R, Menegaux F, Khayat D, Leenhardt L 2012 GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. Med Oncol 29:1421–1428. 1054. Farooki A, Leung V, Tala H, Tu ttle RM 2012 Skeletal- related events due to bone metastases from differen-tiated thyroid cancer. J Clin Endocrinol Metab 97: 2433–2439. 1055. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R, Houston SJ, Grieve RJ, Barrett-Lee PJ, Thorpe H 2011 Safety of zoledronic acid and incidence of osteonecrosis |
of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat 127:429–438. 1056. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D 2005 Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone me- tastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869–1876. 1057. Orita Y, Sugitani I, Toda K, Manabe J, Fujimoto Y 2011 Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma. Thyroid 21:31–35. 1058. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S 2012 Superiority of denosumab to |
zoledronic acid for pre- vention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082–3092. 1059. Cancer Genome Atlas Research Network 2014 In- tegrated genomic characterization of papillary thyroid carcinoma. Cell 159:676–690. 1060. Goldfarb M, Casillas J 2014 Unmet information and support needs in newly diagnosed thyroid cancer: com- parison of adolescents/young adults (AYA) and olderpatients. J Cancer Surviv 8:394–401. 1061. Banach R, Bartes B, Farnell K, Rimmele H, Shey J, Singer S, Verburg FA, Luster M 2013 Results of the Thyroid Cancer Alliance international patient/survivor survey: Psychosocial/informational support needs, treat- ment side effects and international differences in care. Hormones (Athens) 12:428–438. 1062. O’Brien MA, Whelan TJ, Villasis-Keever M, Gafni A, Charles C, Roberts R, Schiff S, Cai W 2009 Are cancer- related decision aids effective? A systematic review and meta-analysis. J Clin Oncol 27:974–985. 1063. Spiegle G, Al-Sukhni E, Schmocker S, Gagliardi |
AR, Victor JC, Baxter NN, Kennedy ED 2013 Patient deci- sion aids for cancer treatment: are there any alternatives? Cancer 119:189–200. 1064. Sawka AM, Straus S, Rotstein L, Brierley JD, Tsang RW, Asa S, Segal P, Kelly C, Zahedi A, Freeman J, Solomon P, Anderson J, Thorpe KE, Gafni A, Rodin G,Goldstein DP 2012 Randomized controlled trial of a computerized decision aid on adjuvant radioactive iodine treatment for patients with early-stage papillary thyroid cancer. J Clin Oncol 30:2906–2911. 1065. Spencer C, Petrovic I, Fatemi S 2011 Current thyro- globulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of fal- sely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab 96:1283–1291. 1066. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Ko- bayashi K, Matsuzuka F, Kuma K, Miyauchi A 2005 Ultrasonographically and anatomopathologically detect-able node metastases |
in the lateral compartment as in- dicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg 29:917–920. 1067. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Ko- bayashi K, Matsuzuka F, Kuma K, Miyauchi A 2006 Clinical significance of metastasis to the central com- partment from papillary microcarcinoma of the thyroid. World J Surg 30:91–99. 1068. Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ 2015 Redifferentiation of iodine-refractory BRAFV600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res 21:1028–1035. 1069. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M 2012 Safety, |
activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. 1070. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM 2012 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465. 1071. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C,Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A 2013 Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med |
369:134–144. 1072. Husson O, Haak HR, Mols F, Nieuwenhuijzen GA, Nieuwlaat WA, Reemst PH, Huysmans DA, Toorians AW, van de Poll-Franse LV 2013 Development of a disease-specific health-related quality of life question- naire (THYCA-QoL) for thyroid cancer survivors. Acta Oncol 52:447–454. 1073. Sawka AM, Naeem A, Jones J, Lowe J, Segal P, Goguen J, Gilbert J, Zahedi A, Kelly C, Ezzat S 2014 Persistent posttreatment fatigue in thyroid cancer survivors: a scoping review. Endocrinol Metab Clin North Am 43: 475–494. 1074. To J, Goldberg AS, Jones J, Zhang J, Lowe J, Ezzat S, Gilbert J, Zahedi A, Segal P, Sawka AM 2014 A sys- tematic review of randomized controlled trials for man-132 HAUGEN ET AL. |
agement of persistent post-treatment fatigue in thyroid cancer survivors. Thyroid 25:198–210. 1075. Bresner L, Banach R, Rodin G, Thabane L, Ezzat S, Sawka AM 2015 Cancer-related worry in Canadian thyroid cancer survivors. J Clin Endocrinol Metab 100:977–985. 1076. Cibas ES, Ali SZ 2009 The Bethesda System For Re- porting Thyroid Cytopathology. Am J Clin Pathol 132: 658–665. 1077. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A 2010 Thyroid cancer staging. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) AJCC Cancer Staging Manual. 7th edition. Springer- Verlag, New York, pp 59–64.1078. Rosario PW, Mineiro Filho AF, Prates BS, Silva LC, Calsolari MR 2012 Postoperative stimulated thyroglob- ulin of less than 1 ng/mL as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid 22:1140–1143. Address correspondence to: Bryan R. Haugen, MD University of Colorado School of |
Medicine Aurora, CO E-mail: [email protected] THYROID NODULE/DTC GUIDELINES 133 |